Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Baycol avoids class action

Executive Summary

Minneapolis federal court denies plaintiffs' motion for class action certification. Bayer had argued that possible claims would have comprised too many diverse and individual issues. Baycol settlements accelerated following initial favorable trial court decisions for Bayer (1"The Pink Sheet" May 12, 2003, p. 20). The company has settled more than 1,342 cases in the U.S. to date...

You may also be interested in...



Bayer’s Baycol Settlements Coming At Quicker Pace; 785 Suits Settled So Far

Bayer has seen the pace of Baycol-related settlements quicken following favorable decisions in the first two cases to come to trial, Finance Division Head Klaus Kühn said during Bayer's May 7 quarterly earnings call

QUOTED. 2 March 2021. Michael Coyle.

Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.

Medicare Drug Pricing Demonstration Agenda May Be Reshaped By Fowler As CMMI Head

Elizabeth Fowler brings combination of Capitol Hill, White House and pharma industry experience to the role of director of the Center for Medicare and Medicaid Innovation.

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel